title: Urological disorders in men: urinary incontinence and benign prostatic hyperplasia.
abstract: Urinary incontinence (UI) and benign prostatic hyperplasia (BPH) are 2 common urogenital problems in men. UI is associated with involuntary leakage of urine and lower urinary tract symptoms (LUTS) of urgency, frequency, and nocturia. Types of UI include functional, urge, stress, and overflow. Treatment for UI is based on the type of incontinence, patient-specific factors, and treatment preferences of both patients and health care providers. Options for the management of UI include environmental modifications, disposable incontinence products, pelvic floor exercises, pharmacotherapy, surgically implanted devices, and intermittent catheterization. BPH may be also associated with LUTS. Patient symptoms, assessed with a measurement tool such as the American Urological Association Symptom Index (AUASI), serve as the basis for determining treatment. Management approaches for BPH include pharmacotherapy, surgery, and minimally invasive procedures. Anticholinergic drugs as well as α-receptor antagonists and 5-α reductase inhibitors, either alone or in combination, are effective and useful for LUTS unresponsive to traditional pharmacotherapy. Transurethral resection of the prostate (TURP) can eliminate symptoms of BPH but is associated with relatively more complications than other available surgical and minimally invasive procedures.
authors: Department of Pharmacy Practice, Mercer University College of Pharmacy and Health Sciences, Atlanta, GA, USA. miller_sw@mercer.edu
authors: Susan W
authors: SW
authors: Miller
authors: Mindi S
authors: MS
authors: Miller
mesh_terms: D058891:5-alpha Reductase Inhibitors / Q000627:therapeutic use*; D018680:Cholinergic Antagonists / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D008297:Male; D011468:Prostatectomy / Q000379:methods*; D011470:Prostatic Hyperplasia / Q000628:therapy*; D012720:Severity of Illness Index; D053201:Urinary Bladder, Overactive / Q000628:therapy*; D014549:Urinary Incontinence / Q000628:therapy*
chemical_list: D058891:5-alpha Reductase Inhibitors; D018680:Cholinergic Antagonists